Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
about
Characterizing Pharmacogenomic-Guided Medication Use With a Clinical Data Repository.Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing.Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov.Potential utility of precision medicine for older adults with polypharmacy: a case series study.Targeted Next-Generation Sequencing for Comprehensive Genetic Profiling of Pharmacogenes.
P2860
Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
@en
Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
@nl
type
label
Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
@en
Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
@nl
prefLabel
Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
@en
Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
@nl
P2860
P50
P356
P1433
P1476
Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
@en
P2860
P2888
P304
P356
10.1038/GIM.2014.181
P407
P577
2014-12-18T00:00:00Z
P6179
1027462297